CANbridge Pharmaceuticals, Inc., a China-based global biopharmaceutical company committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, announced...
AiTA Bio, a New York-based bio-MEMS company, today announced it has secured $8.5 million in Series A funding led by Hammerstone Capital, BlackPoint Partners,...
Shanghai Zhimeng Biopharma, Inc. ("Zhimeng"), announced dosing of the first participant in the US Phase I study in healthy subjects of its innovative small-molecule...
Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, announced enrollment of the first patient in the Strata Precision...
Diagnostics are the foundation of disease detection, diagnosis, and assessment. Diagnostics inform more than 70% of medical decisions about disease treatment, management, and prevention....
